Research progress on the treatment of advanced prostate cancer with Olaparib

被引：3

作者：

Su, Yi-Xin ^{[1
]}

Yu, Cheng-Feng ^{[1
]}

Xue, Peng ^{[1
]}

Li, Lin-Lu ^{[1
]}

Xiao, Kun-Min ^{[1
]}

Chu, Xue-Lei ^{[1
]}

Zhu, Shi-Jie ^{[1
]}

机构：

[1] China Acad Chinese Med Sci, Wangjing Hosp, Beijing, Peoples R China

来源：

NEOPLASMA | 2021年 / 68卷 / 06期

基金：

中国博士后科学基金;

关键词：

Olaparib; advanced prostate cancer; research progress; homologous recombination repair; synthetic lethality; DNA-REPAIR; MAMMARY-TUMORS; INHIBITOR; DAMAGE; RESISTANCE; MUTATIONS; COMBINATION; GENOMICS; THERAPY; BRCA2;

D O I：

10.4149/neo_2021_210627N856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and metastatic castrate-resistant prostate cancer (mCRPC) has shown a poor prognosis. Although chemotherapy and androgen deprivation therapy (ADT) have improved clinical outcomes, the median survival (MS) of patients with mCRPC is still less than 2 years. With the development of poly adenosine diphosphate-ribose polymerase inhibitor (PARPi), the treatment strategy for patients with mCRPC has markedly evolved. Olaparib, a type of PARPi that can selectively induce synthetic lethality in cancer cells with homologous recombination (HR) deficiencies, was the first type of PARPi approved for treating patients with mCRPC harboring mutations in HR repair (HRR) genes. This review discusses and summarizes the latest progress on therapeutic mechanisms, monotherapy, combination therapy, and adverse events of Olaparib.

引用

页码：1132 / 1138

页数：7

共 56 条

[1] Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
Abida, Wassim
Armenia, Joshua
Gopalan, Anuradha
Brennan, Ryan
Walsh, Michael
Barron, David
Danila, Daniel
Rathkopf, Dana
Morris, Michael
Slovin, Susan
McLaughlin, Brigit
Curtis, Kristen
Hyman, David M.
Durack, Jeremy C.
Solomon, Stephen B.
Arcila, Maria E.
Zehir, Ahmet
Syed, Aijazuddin
Gao, Jianjiong
Chakravarty, Debyani
Vargas, Hebert Alberto
Robson, Mark E.
Vijai, Joseph
Offit, Kenneth
Donoghue, Mark T. A.
Abeshouse, Adam A.
Kundra, Ritika
Heins, Zachary J.
Penson, Alexander V.
Harris, Christopher
Taylor, Barry S.
Ladanyi, Marc
Mandelker, Diana
Zhang, Liying
Reuter, Victor E.
Kantoff, Philip W.
Solit, David B.
Berger, Michael F.
Sawyers, Charles L.
Schultz, Nikolaus
Scher, Howard I.
[J]. JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 26
[2] Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Bajrami, Ilirjana
Frankum, Jessica R.
Konde, Asha
Miller, Rowan E.
Rehman, Farah L.
Brough, Rachel
Campbell, James
Sims, David
Rafiq, Rumana
Hooper, Sean
Chen, Lina
Kozarewa, Iwanka
Assiotis, Ioannis
Fenwick, Kerry
Natrajan, Rachael
Lord, Christopher J.
Ashworth, Alan
[J]. CANCER RESEARCH, 2014, 74 (01) : 287 - 297
[3] Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, Louise J.
Sandhu, Shahneen
Chen, Lina
Campbell, James
Kozarewa, Iwanka
Fenwick, Kerry
Assiotis, Ioannis
Rodrigues, Daniel Nava
Reis Filho, Jorge S.
Moreno, Victor
Mateo, Joaquin
Molife, L. Rhoda
De Bono, Johann
Kaye, Stan
Lord, Christopher J.
Ashworth, Alan
[J]. JOURNAL OF PATHOLOGY, 2013, 229 (03) : 422 - 429
[4] Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Brown, Jessica S.
O'Carrigan, Brent
Jackson, Stephen P.
Yap, Timothy A.
[J]. CANCER DISCOVERY, 2017, 7 (01) : 20 - 37
[5] Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations
Carneiro, Benedito A.
Collier, Katharine Ann
Nagy, Rebecca J.
Pamarthy, Sahithi
Sagar, Vinay
Fairclough, Stephen
Odegaard, Justin
Lanman, Richard B.
Costa, Ricardo
Taxter, Timothy
Kuzel, Timothy M.
Fan, Alice
Chae, Young Kwang
Cristofanilli, Massimo
Hussain, Maha H.
Abdulkadir, Sarki A.
Giles, Francis J.
[J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 8
[6] PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, Roman M.
Muirhead, Gareth
Krastev, Dragomir B.
Adam, Julien
Morel, Daphne
Garrido, Marlene
Lamb, Andrew
Henon, Clemence
Dorvault, Nicolas
Rouanne, Mathieu
Marlow, Rebecca
Bajrami, Ilirjana
Cardenosa, Marta Llorca
Konde, Asha
Besse, Benjamin
Ashworth, Alan
Pettitt, Stephen J.
Haider, Syed
Marabelle, Aurelien
Tutt, Andrew N. J.
Soria, Jean-Charles
Lord, Christopher J.
Postel-Vinay, Sophie
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (03) : 1211 - 1228
[7] NICOTINAMIDE MONONUCLEOTIDE ACTIVATION OF A NEW DNA-DEPENDENT POLYADENYLIC ACID SYNTHESIZING NUCLEAR ENZYME
CHAMBON, P
MANDEL, P
WEILL, JD
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1963, 11 (01) : 39 - &
[8] RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
Chapman, J. Ross
Barral, Patricia
Vannier, Jean-Baptiste
Borel, Valerie
Steger, Martin
Tomas-Loba, Antonia
Sartori, Alessandro A.
Adams, Ian R.
Batista, Facundo D.
Boulton, Simon J.
[J]. MOLECULAR CELL, 2013, 49 (05) : 858 - 871
[9] Replication fork stability confers chemoresistance in BRCA-deficient cells
Chaudhuri, Arnab Ray
Callen, Elsa
Ding, Xia
Gogola, Ewa
Duarte, Alexandra A.
Lee, Ji-Eun
Wong, Nancy
Lafarga, Vanessa
Calvo, Jennifer A.
Panzarino, Nicholas J.
John, Sam
Day, Amanda
Crespo, Anna Vidal
Shen, Binghui
Starnes, Linda M.
de Ruiter, Julian R.
Daniel, Jeremy A.
Konstantinopoulos, Panagiotis A.
Cortez, David
Cantor, Sharon B.
Fernandez-Capetillo, Oscar
Ge, Kai
Jonkers, Jos
Rottenberg, Sven
Sharan, Shyam K.
Nussenzweig, Andre
[J]. NATURE, 2016, 535 (7612) : 382 - +
[10] Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M.
Guffanti, F.
Bertoni, F.
Colombo, I.
Damia, G.
[J]. DRUG RESISTANCE UPDATES, 2021, 55

← 1 2 3 4 5 6 →